Aardvark Therapeutics, Inc. · NASDAQ:AARD

Aardvark Therapeutics, Inc. financial statements

Aardvark Therapeutics, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022
Revenue0000
Cost of revenue36.0K16.0K97.0K110.0K
Gross profit-36.0K-16.0K-97.0K-110.0K
Research and development48.9M17.4M4.48M7.17M
Selling, general and administrative13.8M5.30M2.17M2.70M
Operating income-62.7M-22.8M-7.42M-11.4M
Depreciation and amortization36.0K16.0K97.0K110.0K
EBITDA-62.7M-22.8M-7.32M-11.3M
Income before tax-57.6M-20.6M-7.21M-13.6M
Income tax00
Net income-57.6M-20.6M-7.21M-13.6M
Earnings per share, basic-2.93-5.15-0.34-0.63
Earnings per share, diluted-2.93-5.15

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents47.1M61.6M9.73M15.6M
Short-term investments63.0M12.0M254.0K546.0K
Current assets111.9M74.1M10.4M16.5M
Total assets117.2M77.5M10.5M16.8M
Accounts payable2.07M2.30M1.03M259.0K
Current liabilities10.5M4.93M1.38M595.0K
Total debt441.0K779.0K162.0K262.0K
Total liabilities10.5M5.39M45.3M44.7M
Shareholders' equity106.6M-54.6M-34.8M-27.9M
Shares outstanding21.8M4.07M21.4M21.4M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-54.2M-18.1M-5.82M-10.5M
Capital spending-95.0K-109.0K00
Free cash flow-54.3M-18.2M-5.82M-10.5M
Cash from investing-49.7M-12.0M-1.00M
Cash from financing89.2M82.0M0225.0K
Share buybacks195.0K
Change in cash-14.6M51.9M-5.82M-11.3M